ORX Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Orexo AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr22.55 |
52 Week High | kr23.30 |
52 Week Low | kr8.79 |
Beta | 0.62 |
1 Month Change | 13.89% |
3 Month Change | 47.39% |
1 Year Change | 129.63% |
3 Year Change | -43.20% |
5 Year Change | -68.46% |
Change since IPO | -74.94% |
Recent News & Updates
Recent updates
Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
May 29Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Apr 03We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Dec 09Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price
Jun 14Is Orexo (STO:ORX) A Risky Investment?
Apr 27Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price
Oct 19Would Orexo (STO:ORX) Be Better Off With Less Debt?
Sep 09Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?
May 26Is Orexo (STO:ORX) Using Too Much Debt?
Apr 16Orexo (STO:ORX) Has Debt But No Earnings; Should You Worry?
May 04Increases to Orexo AB (publ)'s (STO:ORX) CEO Compensation Might Cool off for now
Apr 06Orexo (STO:ORX) Share Prices Have Dropped 22% In The Last Five Years
Mar 16Nikolaj Sørensen Is The President & CEO of Orexo AB (publ) (STO:ORX) And They Just Picked Up 2.1% More Shares
Feb 17Shareholder Returns
ORX | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | 3.7% | -5.9% | -2.1% |
1Y | 129.6% | 76.4% | 11.2% |
Return vs Industry: ORX exceeded the Swedish Pharmaceuticals industry which returned 82% over the past year.
Return vs Market: ORX exceeded the Swedish Market which returned 12.8% over the past year.
Price Volatility
ORX volatility | |
---|---|
ORX Average Weekly Movement | 6.9% |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.7% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ORX's share price has been volatile over the past 3 months.
Volatility Over Time: ORX's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 113 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
ORX fundamental statistics | |
---|---|
Market cap | kr776.84m |
Earnings (TTM) | -kr73.30m |
Revenue (TTM) | kr619.30m |
1.3x
P/S Ratio-10.6x
P/E RatioIs ORX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ORX income statement (TTM) | |
---|---|
Revenue | kr619.30m |
Cost of Revenue | kr73.50m |
Gross Profit | kr545.80m |
Other Expenses | kr619.10m |
Earnings | -kr73.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 17, 2024
Earnings per share (EPS) | -2.13 |
Gross Margin | 88.13% |
Net Profit Margin | -11.84% |
Debt/Equity Ratio | 810.7% |
How did ORX perform over the long term?
See historical performance and comparison